Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials
- Chang, Joe Y.
- Senan, Suresh
- Paul, Marinus A.
- Mehran, Reza J.
- Louie, Alexander V.
- Balter, Peter
- Groen, Harry J. M.
- McRae, Stephen E.
- Widder, Joachim
- Feng, Lei
- van den Borne, Ben E. E. M.
- Munsell, Mark F.
- Hurkmans, Coen
- Berry, Donald A.
- van Werkhoven, Erik
- Kresl, John J.
- Dingemans, Anne-Marie
- Dawood, Omar
- Haasbeek, Cornelis J. A.
- Carpenter, Larry S.
- De Jaeger, Katrien
- Komaki, Ritsuko
- Slotman, Ben J.
- Smit, Egbert F.
- Roth, Jack A.
Publication date
June 2015
DOIAbstract
Background The standard of care for operable, stage I, non-small-cell lung cancer (NSCLC) is lobectomy with mediastinal lymph node dissection or sampling. Stereotactic ablative radiotherapy (SABR) for inoperable stage I NSCLC has shown promising results, but two independent, randomised, phase 3 trials of SABR in patients with operable stage I NSCLC (STARS and ROSEL) closed early due to slow accrual. We aimed to assess overall survival for SABR versus surgery by pooling data from these trials. Methods Eligible patients in the STARS and ROSEL studies were those with clinical T1-2a
Add to ORKG